Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Non-Current Assets (2019 - 2025)

Historic Non-Current Assets for Biodesix (BDSX) over the last 7 years, with Q3 2025 value amounting to $55.3 million.

  • Biodesix's Non-Current Assets fell 579.81% to $55.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $55.3 million, marking a year-over-year decrease of 579.81%. This contributed to the annual value of $57.8 million for FY2024, which is 278.22% down from last year.
  • According to the latest figures from Q3 2025, Biodesix's Non-Current Assets is $55.3 million, which was down 579.81% from $55.3 million recorded in Q2 2025.
  • Over the past 5 years, Biodesix's Non-Current Assets peaked at $59.4 million during Q4 2023, and registered a low of $32.5 million during Q4 2021.
  • In the last 5 years, Biodesix's Non-Current Assets had a median value of $52.4 million in 2023 and averaged $47.5 million.
  • Per our database at Business Quant, Biodesix's Non-Current Assets plummeted by 700.26% in 2021 and then soared by 5013.9% in 2023.
  • Over the past 5 years, Biodesix's Non-Current Assets (Quarter) stood at $32.5 million in 2021, then increased by 21.82% to $39.6 million in 2022, then soared by 50.14% to $59.4 million in 2023, then fell by 2.78% to $57.8 million in 2024, then decreased by 4.22% to $55.3 million in 2025.
  • Its Non-Current Assets was $55.3 million in Q3 2025, compared to $55.3 million in Q2 2025 and $56.6 million in Q1 2025.